Cat: PA1000-1125

Recombinant Human FHIT Protein,His

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • 基因名

    FHIT

  • Application

    SPRMSTBLIITCELISA细胞实验药物筛选

  • 别名

    FHIT;Bis(5'-adenosyl)-triphosphatase

  • 种属

    Human

  • 表达系统

    E. coli

  • 标签

    His tag N-Terminus

  • 纯度

    Greater than 90% as determined by SDS-PAGE.

  • 蛋白编号

    P49789

  • 表达区间

    1-147aa

  • 氨基酸序列

    MSFRFGQHLI KPSVVFLKTE LSFALVNRKP VVPGHVLVCP LRPVERFHDL RPDEVADLFQ TTQRVGTVVE KHFHGTSLTF SMQDGPEAGQ TVKHVHVHVL PRKAGDFHRN DSIYEELQKH DKEDFPASWR SEEEMAAEAA ALRVYFQLEH HHHHH

  • 分子量

    18 kDa

  • 内毒素

    < 1.0 EU per μg protein as determined by the LAL method.

  • 性状

    Freeze-dried powder

  • 缓冲液

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • 复溶方法

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • 个性化定制

    点位突变 标签定制 buffer定制 全长蛋白定制

  • 稳定性测试

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • 保存条件 & 期限

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • 运输条件

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

FHIT (Fragile Histidine Triad) protein is a tumor suppressor that has garnered significant interest in cancer research due to its role in maintaining genomic stability and its involvement in various cellular processes, including apoptosis and DNA repair. The FHIT gene, located at chromosome 3p14.2, is frequently found to be deleted or mutated in several types of human cancers, particularly those of the lung, bladder, and head and neck. This loss of FHIT expression is correlated with tumor progression and poor prognosis, highlighting its importance in carcinogenesis. Research has focused on understanding the biochemical pathways through which FHIT exerts its tumor suppressive effects, as well as on developing recombinant FHIT protein for therapeutic purposes. Recombinant FHIT has been investigated for its potential application in cancer therapy, particularly as a tool for restoring function in cancer cells that exhibit FHIT loss, thereby reactivating its tumor-suppressive actions. Studies aimed at elucidating the structural and functional properties of the recombinant protein have provided insights into its interactions with other biomolecules and its mechanisms of action. Consequently, the development of recombinant FHIT protein represents a promising avenue for cancer treatment strategies and adds to the growing body of research exploring the therapeutic potential of tumor suppressor proteins.

客服热线

027-8586 6806

E-mail

sales@ipodix.cn

人工客服①

汪经理

18007124176


加微信咨询

人工客服②

简经理

18164034885


加微信咨询
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
  • 30000+

    Recombinant

  • 100+

    Researcher

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US